Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it has been awarded a new $670,621 Small Business Innovation Research (SBIR) grant to advance its Vision Restoration Program, the Company’s proprietary and innovative program generating 3-dimensional human retinal tissue derived from pluripotent cells. Lineage’s Vision Restoration Program aims to address a wide range of severe retinal degenerative conditions including retinitis pigmentosa, advanced forms of age-related macular degeneration (AMD), and ocular trauma. The program and its award are distinct from OpRegen®, the Company’s clinical-stage cell therapy program which features the sub-retinal delivery of retinal pigment epithelium cells for the treatment of dry-AMD.“Grants for ophthalmology research from the NIH are highly competitive and we believe this new award
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024Business Wire
- Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitBusiness Wire
- OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumBusiness Wire
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopBusiness Wire